Lung Cancer Choices©© 5th Edition Menu
About The Editors
Lorren Sandt is a co-founder and the Executive Director of the Caring Ambassadors Program. She managed the Hepatitis C Program of the Caring Ambassadors Program since its inception in 1999 until 2013. Lorren is a co-editor and a contributing author, to Hepatitis C Choices, 4th Edition, a one-of-a-kind, patient-centered book authored by a team of more than 25 multi-disciplined experts in hepatitis C. She has worked on policy changes at both the state and federal level since 2001. Ms. Sandt is a nationally recognized leader in hepatitis advocacy. In 2001, The Hepatitis C Global Foundation honored Ms. Sandt with the Ronald Eugene Duffy Memorial Award for Patient Activism: for leadership and mentoring of patients, making them advocates for their own health. In 2013, The National Viral Hepatitis Roundtable honored Ms. Sandt with the Michael Carden Award for more than a decade of policy work on behalf of those living with viral hepatitis. In 2017, Ms. Sandt received recognition by the Economist Intelligence Unit as a “2017 HCV Change Maker” for Caring Ambassadors significant contribution to the elimination of hepatitis C.
Cindy Langhorne-Hatfield joined the Caring Ambassadors Program, Inc. in August of 2007 as the Lung Cancer Program Director. Ms. Langhorne brings over twenty-three years of programmatic and managerial experience in the field of lung cancer advocacy and has worked with public and private community stakeholders. Cindy’s compassion for patients with lung cancer and their families and her dedication to improving the challenges facing patient with lung cancer one life at a time are extraordinary. Ms. Langhorne-Hatfield is a well-respected local, regional, and national advocate for lung cancer and issues that affect those living with or at risk for the disease. Ms. Langhorne-Hatfield is also the acting Co-Chair for the Lung Cancer Action Network (LungCAN®). LungCAN® is a collaborative group of lung cancer advocacy organizations (30+) and patient and family representation from patients from multiple biomarker groups, who have come together to raise public awareness of the realities of lung cancer with the intention of increasing funding for detecting, treating and curing the disease.